Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

IVIG therapy significantly improved symptoms in a patient with APS-2 and SPS.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.

The treatment effectively reduced hair growth and was safe for patients with PCOS, but it needs better bleeding control.

Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.

PRP works faster and is a safe alternative to steroids for treating alopecia areata.

The IGRA test effectively detects past SARS-CoV-2 exposure, especially using nucleocapsid peptides.

Injecting recipient splenocytes into donors' thymus can prevent graft-versus-host disease.

Hormone therapy for excessive hair growth is as good with GnRHa as with high-dose CPA, but GnRHa has longer-lasting results.

Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.

Recombinant cytokine therapy can cause skin reactions ranging from mild to severe.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Baricitinib is effective and safe for treating severe alopecia areata.

Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.

Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.

Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.

Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.

Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.

Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.

Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.

Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.

The gel improves hair regrowth and reduces irritation in alopecia areata treatment.

The multi-injection plate is a less painful and more efficient method for treating patchy hair loss.

A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.

A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.